Considerations for CPX-351 in Acute Myeloid Leukemia
1 Views
administrator
07/04/23
Expert panelists Eunice Wang, MD; Harry Erba, MD, PhD; Alexander E. Perl, MD; and Jorge E. Cortes, MD, identify important considerations when treating acute myeloid leukemia with CPX-351, such as its toxicity profile and patient stratification.
-
Category
Show more
Facebook Comments
No comments found